Getting to treatment earlier.
Getting to treatment earlier.
CTD refers to a variety of autoimmune disorders with signs and symptoms that overlap with various other diseases, making diagnosis very difficult. That’s why we offer a comprehensive line of test options including NOVA Lite®, QUANTA Lite®, and QUANTA Flash® assays. We continue to develop new assays to help diagnose and stratify CTD disorders, like HMGCR for necrotizing myopathy.
HIGHLIGHTS
- Giving patients earlier answers.Patients gain confidence when their diagnosis is supported by clinical labs results. New biomarkers like HMGCR offer help confirm a diagnosis in areas such as necrotizing myopathy where existing tests don’t cover all forms of the disease.
- Improving workflow in the lab.Assays like QUANTA Flash dsDNA, utilize random access testing to eliminate batching and improve efficiency in your lab.
- Enhancing clinical diagnosis and assessment.Clinicians appreciate the excellent performance characteristics of our CTD assays to aid in the assessment of complex symptoms and diseases.
Reagents
QUANTA Lite® (ELISA)
Description
Package size
Part number
Documents
QUANTA Flash® (CIA)
Description
Package size
Part number
Documents
NOVA Lite® (IFA)
Description
Package size
Part number
Documents
20 X 12 wells (240 tests)
10 X 5 wells (50 tests)
25 X 10 wells (250 tests)
20 X 12 wells (240 tests)
10 X 4 wells (40 tests)
20 X 8 wells (160 tests)
10 X 6 wells (60 tests)
25 X 8 wells (200 tests)
5 X 12 wells (60 tests)